PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability
Protein kinase C α (PKCα) regulates diverse biological functions of cancer cells and is a promising therapeutic target. However, clinical trials of PKC-targeted therapies have not yielded satisfactory results. Recent studies have also indicated a tumor-suppressive role of PKCs via unclear molecular...
Saved in:
Main Authors: | Jiaojiao Yu (Author), Yujin Xiang (Author), Yuzhen Gao (Author), Shan Chang (Author), Ren Kong (Author), Xiaoxi Lv (Author), Jinmei Yu (Author), Yunjie Jin (Author), Chenxi Li (Author), Yiran Ma (Author), Zhenhe Wang (Author), Jichao Zhou (Author), Hongyu Yuan (Author), Shuang Shang (Author), Fang Hua (Author), Xiaowei Zhang (Author), Bing Cui (Author), Pingping Li (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
by: Yiting Wang, et al.
Published: (2018) -
Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
Published: (2020) -
Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
by: Yiting Wang, et al.
Published: (2020) -
Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
by: Xiujing He, et al.
Published: (2022) -
Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
by: Aaron Prodeus, et al.
Published: (2015)